Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Dynasore. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 5/20 | 0.65 |
| ▸ | RRM1 known ✓ | P23921 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.97 |
| ▸ | ECE2 | P0DPD6 | 2/20 | 0.97 |
| ▸ | ECE1 | P42892 | 2/20 | 0.97 |
| ▸ | MUS81 | Q96NY9 | 2/20 | 0.97 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | AR | P10275 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MGAM | O43451 | 1/20 | 0.61 |
| ▸ | SI | P14410 | 1/20 | 0.61 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.58 |
| ▸ | ALPL | P05186 | 1/20 | 0.58 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | ALPG | P10696 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dynasore SCHEMBL30961945 | 0.99 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| Dynasore SCHEMBL4570231 | 0.99 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| Dynasore SCHEMBL29385895 | 0.99 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| Dynasore SCHEMBL30917221 | 0.99 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| Dynasore SCHEMBL847982 | 0.99 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| Dynasore SCHEMBL29695524 | 0.99 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| Dynasore SCHEMBL16342920 | 0.99 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| SCHEMBL14983909 | 0.89 | DNM1 (0.82) | DNM1ECE2ECE1MUS81NTRK1 | |
| SCHEMBL25474226 | 0.87 | DNM1 (0.79) | DNM1ECE2ECE1MUS81NTRK1 | |
| SCHEMBL18876543 | 0.87 | DNM1 (0.79) | DNM1ECE2ECE1MUS81NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085617-A1 | METHOD OF ANALYZING LIGAND-RECEPTOR COMPLEXES | YYZ PHARMATECH INC. (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-12427183-B2 | Methods of treating cancer, infectious disease, and autoimmune disease using chemokines | New York Society For The Relief Of The Ruptured And Crippled, The Hospital For Maintaining, Special Surgery (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250009779-A1 | METHODS FOR TREATING VIRAL DISEASES | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY | 2025-01-09 | — | — | US | disclosed |
| EP-4415702-A1 | METHODS FOR TREATING VIRAL DISEASES | New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special Surgery (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2024129990-A2 | CHEMICALLY MODIFIED AAVS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023064356-A1 | METHODS FOR TREATING VIRAL DISEASES | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20220275371-A1 | USE OF RAB7 GTPASE (RAB7) INHIBITORS IN ENHANCING PERMEABILITY OF THE BLOOD BRAIN BARRIER (BBB) | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-09-01 | — | — | US | disclosed |
| US-20220072100-A1 | METHODS OF TREATING CANCER, INFECTIOUS DISEASE, AND AUTOIMMUNE DISEASE USING CHEMOKINES | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009779-A1 | METHODS FOR TREATING VIRAL DISEASES | NFATC1, EIF2AK2, MAVS | MEN1 4826/4885RRM1 3958/4885DNM1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.